Blood Res.  2023 Apr;58(S1):109-113. 10.5045/br.2023.2023054.

Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplantation

• Uhm J

• KMID: 2541989
• DOI: http://doi.org/10.5045/br.2023.2023054

Abstract

The treatment outcomes of chronic myeloid leukemia in chronic phase (CML-CP) have dramatically improved with comparable life-expectancy to average of general population in tyrosine kinase inhibitor (TKI) era. However, less than a half of patients who started with TKI can remain on frontline TKI. The reasons of switching TKI can be either intolerance or the lack of efficacy. Although a kinase domain (KD) mutation can guide to select salvage TKI from the point of view on the efficacy of TKIs, many factors need to be considered before choosing next-line TKI such as the high-risk features of CML, the adverse events with prior TKI, and the comorbidities of patients. The therapeutic options for CML-CP after failing frontline TKI due to treatment failure or suboptimal responses will be reviewed including allogeneic hematopoietic stem cell transplantation.

Keyword

Chronic myeloid leukemia; Tyrosine kinase inhibitors; Ponatinib; Asciminib; Allogeneic hematopoietic stem cell transplantation